Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2016

01-08-2016 | Editorial

Fecal Microbiota Transplantation for Ulcerative Colitis: FoMenTing Change?

Author: Flaviano S. Martins

Published in: Digestive Diseases and Sciences | Issue 8/2016

Login to get access

Excerpt

Fecal microbiota transplant (FMT), the process of introducing fecal bacteria from a healthy donor into a diseased patient, has gained increasing attention since it was established as an effective treatment for patients suffering from infection with Clostridium difficile (CD), the pathogenic bacterium responsible for pseudomembranous colitis and for some antibiotic-associated diarrhea. Due to the mounting failure experienced with eliminating this bacterium with conventional therapies, alternative treatments have been used, of which the most promising is FMT [1]. The concept of using feces to treat gastrointestinal diseases was first documented in China in the fourth century and in the USA in 1958 [2, 3]. In 2013, a randomized controlled trial published in The New England Journal of Medicine concluded that FMT is significantly more effective for the treatment of recurrent CD infection (CDI) than the use of antibiotics [4]. …
Literature
1.
go back to reference Brown WR. Fecal microbiota transplantation in treating Clostridium difficile infection. J Dig Dis. 2014;15:405–408.CrossRefPubMed Brown WR. Fecal microbiota transplantation in treating Clostridium difficile infection. J Dig Dis. 2014;15:405–408.CrossRefPubMed
2.
go back to reference Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012;107:1755.CrossRefPubMed Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012;107:1755.CrossRefPubMed
3.
go back to reference Eiseman B, Silen W, Bascon GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854–859.PubMed Eiseman B, Silen W, Bascon GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854–859.PubMed
4.
go back to reference van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415.CrossRefPubMed van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415.CrossRefPubMed
6.
go back to reference Ghouri YA, Richards DM, Rahimi EF, et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473–487.PubMedPubMedCentral Ghouri YA, Richards DM, Rahimi EF, et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473–487.PubMedPubMedCentral
7.
go back to reference Souza ÉL, Elian SD, Paula LM, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, inflammatory response and clinical signs in a faecal transplantation model. J Med Microbiol. 2016. doi:10.1099/jmm.0.000222. Souza ÉL, Elian SD, Paula LM, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, inflammatory response and clinical signs in a faecal transplantation model. J Med Microbiol. 2016. doi:10.​1099/​jmm.​0.​000222.
8.
go back to reference Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102–109.CrossRefPubMed Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102–109.CrossRefPubMed
9.
go back to reference Tian Z, Liu J, Liao M, et al. Beneficial effects of fecal microbiota transplantation on ulcerative colitis in mice. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-016-4060-2. Tian Z, Liu J, Liao M, et al. Beneficial effects of fecal microbiota transplantation on ulcerative colitis in mice. Dig Dis Sci. (Epub ahead of print). doi:10.​1007/​s10620-016-4060-2.
10.
go back to reference Elian SD, Souza EL, Vieira AT, et al. Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease. Benef Microbes. 2015;6:277–286.CrossRefPubMed Elian SD, Souza EL, Vieira AT, et al. Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease. Benef Microbes. 2015;6:277–286.CrossRefPubMed
11.
go back to reference Tiago FC, Porto BA, Ribeiro NS, et al. Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease. Benef Microbes. 2015;6:807–815.CrossRefPubMed Tiago FC, Porto BA, Ribeiro NS, et al. Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease. Benef Microbes. 2015;6:807–815.CrossRefPubMed
Metadata
Title
Fecal Microbiota Transplantation for Ulcerative Colitis: FoMenTing Change?
Author
Flaviano S. Martins
Publication date
01-08-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4133-2

Other articles of this Issue 8/2016

Digestive Diseases and Sciences 8/2016 Go to the issue